Table 3.
Hazard ratios of breast cancer across tertiles of BMI by clusters of breast tumors from hierarchical clustering (see Fig. 1)a
| Postmenopausal non-users of HTb | Postmenopausal users of HTb | Pre- and perimenopausal womenb | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases (n) | HR | CI (95%) | Cases (n) | HR | CI (95%) | Cases (n) | HR | CI (95%) | ||||
| Cluster 1 | Tertile 1 | 4 | 1 | Tertile 1 | 30 | 1 | Tertile 1 | 59 | 1 | |||
| (ER+, PR+, HER2-, Ki67 low , bcl-2+, and p53-) | Tertile 2 | 8 | 1.02 | (0.31,3.40) | Tertile 2 | 32 | 0.74 | (0.44,1.22) | Tertile 2 | 31 | 0.64 | (0.41,1.00) |
| Tertile 3 | 33 | 2.50 | (0.86,7.23) | Tertile 3 | 24 | 0.61 | (0.35,1.06) | Tertile 3 | 21 | 0.55 | (0.33,0.93) | |
| Per 5 kg/m 2 | 1.44 | (1.10,1.90) | Per 5 kg/m 2 | 0.68 | (0.50,0.94) | Per 5 kg/m 2 | 0.85 | (0.67,1.08) | ||||
| p trend | 0.009 | p trend | 0.018 | p trend | 0.19 | |||||||
| Cluster 2 | Tertile 1 | 5 | 1 | Tertile 1 | 10 | 1 | Tertile 1 | 18 | 1 | |||
| (ER- or ER+ that are Bcl-2-) | Tertile 2 | 6 | 0.77 | (0.23,2.56) | Tertile 2 | 18 | 1.14 | (0.52,2.53) | Tertile 2 | 9 | 0.59 | (0.26,1.32) |
| Tertile 3 | 16 | 1.40 | (0.49,4.04) | Tertile 3 | 6 | 0.43 | (0.15,1.21) | Tertile 3 | 20 | 1.52 | (0.77,3.00) | |
| Per 5 kg/m 2 | 1.15 | (0.78,1.70) | Per 5 kg/m 2 | 0.83 | (0.52,1.32) | Per 5 kg/m 2 | 1.22 | (0.91,1.62) | ||||
| p trend | 0.47 | p trend | 0.42 | p trend | 0.18 | |||||||
| Cluster 3 | Tertile 1 | 5 | 1 | Tertile 1 | 20 | 1 | Tertile 1 | 48 | 1 | |||
| (ER+ with at least one other marker indicative of higher aggressiveness) | Tertile 2 | 21 | 2.98 | (1.01,8.75) | Tertile 2 | 33 | 1.20 | (0.68,2.12) | Tertile 2 | 26 | 0.72 | (0.44,1.18) |
| Tertile 3 | 16 | 1.57 | (0.51,4.83) | Tertile 3 | 17 | 0.77 | (0.39,1.51) | Tertile 3 | 31 | 1.13 | (0.70,1.82) | |
| Per 5 kg/m 2 | 1.00 | (0.71,1.42) | Per 5 kg/m 2 | 0.82 | (0.58,1.15) | Per 5 kg/m 2 | 0.94 | (0.74,1.19) | ||||
| p trend | 0.99 | p trend | 0.24 | p trend | 0.60 | |||||||
Median (p25, p75) values of BMI: Tertile 1: 21.4 (20.4, 22.3), Tertile 2: 24.8 (23.9, 25.7); Tertile 3: 29.9 (28.1, 32.7)
No statistical heterogeneity of HRs across subtypes was observed
aFrom Cox regression models adjusted for height, number of full-term pregnancies, pill use, education level, smoking status, and study center bAt baseline (HT hormone therapy)